Home > Resources > Company Profiles > Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY)

PRINT
SHARE
TEXT SIZE:
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Letters are not case-sensitive, disregard spaces.
captcha image
Try a New One
This helps us prevent automated registrations and spamming.
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Dr. John M. Maraganore, Ph.D., CEO/Director

300 Third Street

Cambridge, MA 02142

US Map it

Phone: (617) 551-8200

Fax: (617) 551-8101

www.alnylam.com



Overview

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Employees

Number of Employees: 129
Revenue per Employee: $324,967

Top Executives

Barry E. Greene, COO/President
Patricia L. Allen, CPA, Divisional Vice President/Treasurer/CFO

Board of Directors

Patricia L. Allen, CPA, Divisional Vice President/Treasurer/CFO
Dr. Vicki L. Sato, Director
John K. Clarke, Chairman of the Board/Director/Founder

Financials

Quarterly
Annual

Income Statement 05/2008 02/2008 11/2007 08/2007
Sales NA NA -1.05 Mil. -937 K.
Gross Operating Profit 22.19 Mil. 18.23 Mil. 17.36 Mil. 10.07 Mil.
Operating Income before D & A (EBITDA) -3.96 Mil. -2.89 Mil. -50.29 Mil. -14.02 Mil.
Total Income Before Interest Expenses (EBIT) -802 K. 1.97 Mil. -47.34 Mil. -12.42 Mil.
Total Net Income -1.24 Mil. 1.66 Mil. -52.79 Mil. -12.69 Mil.
Basic EPS, Total -0.03 0.04 -1.35 -0.34
Diluted EPS, Total -0.03 0.04 -1.35 -0.34

BALANCE STATEMENT 05/2008 02/2008 11/2007 08/2007
Cash and Equivalents 443.87 Mil. 455.6 Mil. 200.55 Mil. 84.46 Mil.
Total Assets NA 463.56 Mil. 477.63 Mil. 201.96 Mil.
Total Liabilities 26.09 Mil. 289.12 Mil. 87.46 Mil. 27.11 Mil.
Total Capitalization 204.77 Mil. 199.17 Mil. 196.88 Mil. 184.18 Mil.

Cash Flow 05/2008 02/2008 11/2007 08/2007
Net Cash From Continuing Operations NA NA 204.96 Mil. -19.35 Mil.
Net Cash From Investing Activities NA NA -189.74 Mil. -23.85 Mil.
Net Cash From Financing Activities NA NA 57.88 Mil. -93 K.
Net Change in Cash & Cash Equivalents NA NA 72.59 Mil. -43.49 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales NA -3.82 Mil. -3.12 Mil. -2.44 Mil.
Gross Operating Profit 50.9 Mil. 30.74 Mil. 8.84 Mil. 6.72 Mil.
Operating Income before D & A (EBITDA) -93.18 Mil. -35.69 Mil. -40.35 Mil. -29.82 Mil.
Total Income Before Interest Expenses (EBIT) -79.14 Mil. -33.58 Mil. -41.94 Mil. -31.99 Mil.
Total Net Income -85.47 Mil. -34.61 Mil. -42.91 Mil. -32.65 Mil.
Basic EPS, Total -2.21 -1.09 -1.96 -2.98
Diluted EPS, Total -2.21 -1.09 -1.96 -2.98

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 455.6 Mil. 127.96 Mil. 15.76 Mil. 20.27 Mil.
Total Assets 463.56 Mil. 222.78 Mil. 82.41 Mil. 48.18 Mil.
Total Liabilities 289.12 Mil. 22.92 Mil. 18.48 Mil. 6.58 Mil.
Total Capitalization 199.17 Mil. 207.09 Mil. 67.3 Mil. 52.55 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations NA -24.63 Mil. -16.48 Mil. -19.57 Mil.
Net Cash From Investing Activities NA -30.05 Mil. -40.42 Mil. -34.6 Mil.
Net Cash From Financing Activities NA 166.63 Mil. 52.62 Mil. 50.98 Mil.
Net Change in Cash & Cash Equivalents NA 112.2 Mil. -4.52 Mil. -2.92 Mil.

powered by Interactive Data





Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Medicis Pharmaceutical Corporation
1.26 Bil.
Lifecell Corporation
1.35 Bil.
Medarex, Inc.
1.17 Bil.
Theravance, Incorporated
1.14 Bil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

  • If you have a change request regarding a publicly traded company, click here
  • If your request pertains to a private company, click here
Also in Portfolio.com
Most Emailed
Recently Commented